Overall survival and prognostic factors of oral cavity and oropharyngeal squamous cell carcinomas in Saudi Arabia: a population-based cohort study (2000–2019) - Top-Institutions - MDSpire

Overall survival and prognostic factors of oral cavity and oropharyngeal squamous cell carcinomas in Saudi Arabia: a population-based cohort study (2000–2019)

  • By

  • Waad R. Al-Amri

  • Abdullah S. Al-Swuailem

  • June 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    King Faisal Specialist Hospital & Research Centre
    King Faisal Specialist Hospital & Research Centre

    Riyadh, Saudi Arabia

    Key Differentiators

    • Oncology
    • Head & Neck Surgery

  • #2

    Ministry of National Guard Health Affairs – King Abdulaziz Medical City
    Ministry of National Guard Health Affairs – King Abdulaziz Medical City

    Riyadh, Saudi Arabia

    Key Differentiators

    • Oncology
    • Head & Neck Surgery

  • #3

    Cleveland Clinic Cancer Institute
    Cleveland Clinic Cancer Institute

    Cleveland, Ohio

    Key Differentiators

    • Oncology
    • Radiation Oncology

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Head & Neck Surgery

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Head & Neck Surgery

Original Source(s)

Overall survival and prognostic factors of oral cavity and oropharyngeal squamous cell carcinomas in Saudi Arabia: a population-based cohort study (2000–2019)

  • by Waad R. Al-Amri, Abdullah S. Al-Swuailem

  • June 11, 2026

Related Content

MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer